Panelists discuss how they evaluate patients postsurgically by weighing factors like tumor location, extent of resection, patient age, and quality of life considerations to determine whether to pursue immediate treatment or surveillance, while emphasizing that microscopic disease always remains despite apparent gross total resection.
Content above is prompted by the following:
Postsurgical management decisions require careful evaluation of multiple factors including tumor location, extent of resection, molecular profile, patient age, symptoms, and individual preferences. The multidisciplinary team approach proves essential in weighing immediate intervention vs observation, particularly considering the favorable prognosis of IDH-mutant gliomas and the typically young patient population. Factors such as fertility concerns, career considerations, and quality of life priorities significantly influence treatment timing decisions.
Patient education about the infiltrative nature of gliomas remains crucial, with clinicians explaining that even "gross total resection" leaves microscopic disease behind. The iceberg analogy effectively illustrates how visible tumor on MRI represents only a portion of the actual disease burden, with extensive microscopic infiltration beyond imaging detection. This understanding helps patients comprehend why surveillance remains necessary and why tumors typically recur over time, while also explaining the rationale for systemic therapies that can address infiltrative disease.
Surveillance imaging plays a central role in ongoing management, with serial MRI scans guiding treatment decisions based on tumor progression patterns. Increasing FLAIR signal, new areas of involvement, or development of enhancement may trigger treatment initiation. The concept of staying ahead of the disease through regular monitoring enables timely intervention while maximizing quality of life during observation periods. This approach recognizes that IDH-mutant gliomas offer a longer therapeutic window compared to more aggressive tumors, allowing for personalized timing of interventions.
Stay up to date on recent advances in the multidisciplinary approach to cancer.
Prolaris in Practice: Guiding ADT Benefits, Clinical Application, and Expert Insights From ACRO 2025
August 1st 2025Steven E. Finkelstein, MD, DABR, FACRO discuses how Prolaris distinguishes itself from other genomic biomarker platforms by providing uniquely actionable clinical information that quantifies the absolute benefit of androgen deprivation therapy when added to radiation therapy, offering clinicians a more precise tool for personalizing prostate cancer treatment strategies.
Recap: Recent Advances in the Treatment of Metastatic Castration-Sensitive Prostate Cancer
August 1st 2025Expert oncologists review key studies in the metastatic castration-resistant prostate cancer treatment landscape and discuss how evidence can be applied to clinical practice to improve patient outcomes.
CCR Scores and Beyond: Precision Strategies for Treatment Intensification in Prostate Cancer
August 1st 2025Alvaro Martinez, MD discusses how emerging genomic risk stratification tools such as the clinical cell-cycle risk (CCR) score are transforming personalized prostate cancer treatment by enabling more nuanced assessments of metastasis risk and treatment intensification strategies beyond traditional NCCN risk groupings.
Recap: Updates in Treatment of HER2-Positive Breast Cancer and Brain Metastases
August 1st 2025Sara A. Hurvitz, MD; Stefania Maraka, MD; and Ruta Rao, MD, discuss the evolving landscape of metastatic HER2+ breast cancer, highlighting recent clinical trials and the management of patients with brain metastases.
Recap: Emory Experts Review Treatment Strategies for Transplant-Ineligible Multiple Myeloma
August 1st 2025A panel of experts from Emory University review several key data updates in multiple myeloma from recent meetings and discuss how the data can be applied to clinical practice to improve patient outcomes.